Overall, TRIM22 promotes autophagic osteosarcoma cell death and inhibits osteosarcoma progression by promoting NRF2 proteasomal degradation, activating the ROS/AMPK/mTOR/autophagy signaling [38]. The gene discussed is MTOR; the disease is osteosarcoma.